Transitional Drugs 7

Procurement reference

PHA-FTS-62154

Procurement description

This is a contract for the provision of Drugs that have recently lost patent - Eculizumab, Tocilizumab, Nintedanib and Omalizumab

Main category

Goods

Delivery regions

• UKL - Wales

Total value (estimated)

53566932.00 GBP Excluding VAT

64280318.00 GBP Including VAT

Contract dates (estimated)

01 July 2026, 00:00AM to 30 June 2028, 23:59PM

Extension end date (if all the extensions are used): 30 June 2030

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

Is the total value above threshold?

Above threshold

CPV classifications

• 33600000 - Pharmaceutical products

Delivery regions

• UKL - Wales

Sustainability

Small and medium-sized enterprises (SME)

Contract start date (estimated)

01 July 2026, 00:00AM

Contract end date (estimated)

30 June 2028, 23:59PM

Extension end date (estimated)

30 June 2030, 23:59PM

Can the contract be extended?

Yes

Engagement process description

This notice is being issued to advise suppliers of a forthcoming opportunity that is due to be published by Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts).

There is no formal engagement process for this opportunity. Any suppliers who may like more information on this opportunity before the tender is published, please contact Jennifer Tresilian (jennifer.tresilian@wales.nhs.uk)

Due date

09 April 2026, 23:59PM

Has the engagement period already ended?

No

Publication date of tender notice (estimated)

10 April 2026